tiprankstipranks
Trending News
More News >
Kronos Bio, Inc. (KRON)
NASDAQ:KRON
US Market
Advertisement

Kronos Bio (KRON) Price & Analysis

Compare
192 Followers

KRON Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
New Development CandidateKronos announced the nomination of KB-9798 as a development candidate for Sjogren's disease, initiating IND-enabling studies.
Preclinical DevelopmentsKronos is conducting IND-enabling studies for KB-9558 and expects to be IND-ready by the end of 2024, with potential therapeutic roles in HPV-driven cancers.
Strategic PlanningKronos plans to implement significant expense reduction strategies while it explores potential avenues to maximize stakeholder value including acquisitions, mergers, or sales of assets.
Bears Say
Clinical DevelopmentKronos is discontinuing development of istisociclib (KB-0742) due to CNS AEs in ovarian cancer patients.
Safety ConcernsOut of 7 enrolled PROC patients, 5 exhibited neurological events ranging from Grade 1-3 in severity, with 3 discontinuing treatment.

Financials

Ownership Overview

27.02%3.99%17.99%96.01%
27.02% Insiders
17.99% Other Institutional Investors
96.01% Public Companies and
Individual Investors

KRON FAQ

What was Kronos Bio, Inc.’s price range in the past 12 months?
Kronos Bio, Inc. lowest stock price was $0.65 and its highest was $1.60 in the past 12 months.
    What is Kronos Bio, Inc.’s market cap?
    Kronos Bio, Inc.’s market cap is $53.65M.
      When is Kronos Bio, Inc.’s upcoming earnings report date?
      Kronos Bio, Inc.’s upcoming earnings report date is Aug 07, 2025 which is in 11 days.
        How were Kronos Bio, Inc.’s earnings last quarter?
        Currently, no data Available
        Is Kronos Bio, Inc. overvalued?
        According to Wall Street analysts Kronos Bio, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Kronos Bio, Inc. pay dividends?
          Kronos Bio, Inc. does not currently pay dividends.
          What is Kronos Bio, Inc.’s EPS estimate?
          Kronos Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Kronos Bio, Inc. have?
          Kronos Bio, Inc. has 60,969,000 shares outstanding.
            What happened to Kronos Bio, Inc.’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Kronos Bio, Inc.?
            Currently, no hedge funds are holding shares in KRON

            Company Description

            Kronos Bio, Inc.

            Kronos Bio, Inc. (KRON) is a biotechnology company dedicated to discovering and developing novel cancer therapeutics. With a focus on targeting dysregulated transcription, Kronos Bio aims to address difficult-to-treat cancers by exploiting transcriptional dependencies. The company's pipeline includes small molecule therapies designed to modulate transcription factors, which are often implicated in cancer progression.
            Similar Stocks
            Company
            Price & Change
            Follow
            Verrica Pharmaceuticals
            Sutro Biopharma
            Serina Therapeutics
            PMV Pharmaceuticals
            Gain Therapeutics
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis